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Douglas O. Faigel, MD5
Cleveland, Cincinnati, Ohio; Portland, Oregon; Scottsdale, Arizona, USABackground and Aims: Sedation for GI endoscopy directed by anesthesia professionals (ADS) is used with the
intention of improving throughput and patient satisfaction. However, data on its safety are sparse because of the
lack of adequately powered, randomized controlled trials comparing it with endoscopist-directed sedation (EDS).
This study was intended to determine whether ADS provides a safety advantage when compared with EDS for
EGD and colonoscopy.
Methods: This retrospective, nonrandomized, observational cohort study used the Clinical Outcomes Research
Initiative National Endoscopic Database, a network of 84 sites in the United States composed of academic,
community, health maintenance organization, military, and Veterans Affairs practices. Serious adverse events
(SAEs) were deﬁned as any event requiring administration of cardiopulmonary resuscitation, hospital or emer-
gency department admission, administration of rescue/reversal medication, emergency surgery, procedure
termination because of an adverse event, intraprocedural adverse events requiring intervention, or blood
transfusion.
Results: There were 1,388,235 patients in this study that included 880,182 colonoscopy procedures (21% ADS)
and 508,053 EGD procedures (23% ADS) between 2002 and 2013. When compared with EDS, the propensity-
adjusted SAE risk for patients receiving ADS was similar for colonoscopy (OR, .93; 95% CI, .82-1.06) but higher
for EGD (OR, 1.33; 95% CI, 1.18-1.50). Additionally, with further stratiﬁcation by American Society of Anesthesi-
ologists (ASA) class, the use of ADS was associated with a higher SAE risk for ASA I/II and ASA III subjects under-
going EGD and showed no difference for either group undergoing colonoscopy. The sample size was not
sufﬁcient to make a conclusion regarding ASA IV/V patients.
Conclusions:Within the conﬁnes of the SAE deﬁnitions used, use of anesthesia professionals does not appear to
bring a safety beneﬁt to patients receiving colonoscopy and is associated with an increased SAE risk for ASA I, II,
and III patients undergoing EGD. (Gastrointest Endosc 2017;85:101-8.)ns: ADS, anesthesia-directed sedation; ASA, American Society
ologists; CORI, Clinical Outcomes Research Initiative; EDS,
-directed sedation; NED, National Endoscopic Database;
tio; SAE, serious adverse event.
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A safety analysis of 1.38 million sedation procedures Vargo et alSedation is an integral part of most GI endoscopic
procedures performed in the United States. The goals of
sedation are to improve the patient experience by
reducing pain and anxiety, ultimately leading to better
compliance with recommended screenings and follow-
up.1 Sedation options are primarily either endoscopists
targeting minimal to moderate sedation (endoscopist-
directed sedation [EDS]) or anesthesia professionals
typically targeting deep sedation or general anesthesia
(anesthesia-directed sedation [ADS]). Anesthesia
professionals have become increasingly involved in
sedation for screening colonoscopies, rising from 11% in
2001 to 53.4% in 2015.2,3 This increase is likely because
of a perceived increase in satisfaction and throughput
with propofol sedation compared with narcotic/
benzodiazepine-based sedation.4 This practice is
increasing overall procedural costs by approximately 20%.2
The Centers for Medicare & Medicaid Services recently
released a ruling to ensure coverage of anesthesia services
for screening colonoscopies instead of placing the burden
on the patient.5 The costs for involving anesthesia
professionals are substantial.3 An important inquiry
therefore is what beneﬁt is brought to the patient by
using anesthesia professionals in regard to patient safety
and the quality of the procedure.2,6 The aim of better
health care at a reduced cost has become a driving initia-
tive that forces the health care system to ask this question.7
With regard to colonoscopy, several studies have ad-
dressed the method of sedation used and the effect on ad-
enoma detection rates, a measure of quality of the
procedure. One study showed no difference in the detec-
tion of polyps using moderate or deep sedation.8
Similarly, other studies comparing propofol delivered by
an anesthesiologist and endoscopist-directed midazolam/
fentanyl-based sedation found no differences in the num-
ber of patients who had adenomatous polyps detected.9,10
Without a clear beneﬁt in the quality of the colonoscopic
examination, the increased cost for the use of ADS could
potentially be justiﬁed by improved safety. An appropriately
powered randomized, prospective, controlled trial would
be impractical because of the rarity of signiﬁcant events,
but a few investigators have conducted retrospective
studies. An increased rate of perforations during colonos-
copies under propofol sedation and an increased risk of
aspiration pneumonia with sedation delivered by anesthesia
professionals have been observed.11-13 With this landscape
in mind, we examined the National Endoscopic Database
(NED) created by the Clinical Outcomes Research Initiative
(CORI) spanning the years 2002 to 2013 to understand what
role ADS may have in improving patient safety.METHODS
The data for this study came from the NED, a database
of GI endoscopy procedure reports. The database is102 GASTROINTESTINAL ENDOSCOPY Volume 85, No. 1 : 2017created and maintained by CORI, a large multicenter
consortium of gastroenterology practices. From 2002 to
2013, 84 practice sites, including university medical
centers, Veteran Affairs Health Care Systems, and GI
private practices, contributed procedure reports to the
database. Demographic, provider, and procedure data
were collected in patients 18 years of age and older for
all EGDs and colonoscopies over this time period. Partici-
pating sites agree to use a structured computerized report
generator to produce all endoscopic reports and comply
with quality-control requirements. Each site’s data ﬁles
are transmitted electronically to a central data repository,
the NED. Data transmitted from the local site to the NED
do not contain most patient identiﬁers and qualify as a
Limited Data Set under 45 C.F.R. Section 164.514(e). The
NED is reviewed by the institutional review board of the
Oregon Health & Science University (eIRB no. 7331) and
was most recently approved in September 2014. This study
used a limited data set and was therefore exempted from
further institutional review board review.
Primary outcome variable
The primary outcome variable was deﬁned as a serious
adverse event (SAE) requiring intervention. This was
deﬁned as any event requiring administration of cardiopul-
monary resuscitation, hospital or emergency department
admission, administration of rescue/reversal medication,
emergency surgery, procedure termination because of an
adverse event, intraprocedural adverse events requiring
intervention, or blood transfusion.
Independent variable of interest
The independent variable of interest was the specialty of
the health care provider who was directly responsible for
the administration of procedural sedation, as documented
in the CORI procedure report. This was deﬁned as an anes-
thesia professional (ADS), such as an anesthesiologist or
nurse anesthetist, or a nonanesthesia professional (EDS),
speciﬁcally the endoscopist or other nonanesthesiologist
procedure staff. Those sedation providers with ambiguous
status (eg, “physician,” “resident,” and “technician”) were
considered to be unknown and were excluded from the
analysis.
Statistical analysis
Data were analyzed using both multivariate logistic
regression modeling and propensity score analyses. Ana-
lyses involving propensity scores included adjusting for
propensity. All analyses were performed using SAS version
9.4 software (SAS Institute, Cary, NC).
Multivariate logistic regression model
Separate multivariate logistic regression models were
created for colonoscopies and EGDs, modeling the like-
lihood of SAEs. Both models adjusted for patient age,
gender, American Society of Anesthesiologists (ASA)www.giejournal.org
TABLE 1. Demographics
Colonoscopy
(n [ 880,182)
EGD
(n [ 508,053)
Mean age, y (SD) 60.1 (12.5) 58.4 (15.9)
ASA classification
Unknown 61,046 (6.9) 37,112 (7.3)
I 179,866 (20.4) 80,920 (15.9)
II 561,670 (63.8) 295,028 (58.1)
III 75,255 (8.5) 88,046 (17.3)
IV 2,312 (.3) 6,812 (1.3)
V 33 (.0) 135 (.03)
Gender
Female 410,122 (46.6) 245,097 (48.2)
Male 470,060 (53.4) 262,956 (51.8)
Race
Black 52,659 (6.0) 35,428 (7.0)
White 793,539 (90.2) 448,945 (88.4)
Other 33,984 (3.9) 23,680 (4.7)
Location
Outpatient 800,187 (90.9) 413,941 (81.5)
Inpatient 25,260 (2.9) 52,378 (10.3)
Unknown 54,735 (6.2) 41,734 (8.2)
GI trainee
Present 106,806 (12.1) 99,680 (19.6)
Not present 773,376 (87.9) 408,373 (80.4)
Site
Academic 89,060 (10.1) 84,630 (16.7)
VA/military 148,818 (16.9) 87,912 (17.3)
Community/HMO/private
practice
642,304 (73.0) 335,511 (66.0)
Sedation provider
Anesthesia professional 182,694 (20.8) 115,320 (22.7)
Non–anesthesia professional 697,488 (79.2) 392,733 (77.3)
Values are number of cases with percents in parentheses, unless otherwise indicated.
SD, Standard deviation; ASA, American Society of Anesthesiologists; VA, Veterans
Affairs; HMO, health maintenance organization.
Vargo et al A safety analysis of 1.38 million sedation proceduresclassiﬁcation, narcotic medication administered (yes or
no), was a sedative administered (yes or no), sedation pro-
vider status (ADS vs EDS), involvement of fellow or other
trainee in the procedure, practice type (community/health
maintenance organization, academic, or Veterans Affairs/
military), and a select group of procedure indications.
The procedure indications for colonoscopy are screening,
surveillance, positive fecal occult blood test, and unde-
ﬁned. For EGD the indications are Barrett’s screening/sur-
veillance, gastric polyps/ulcer, Helicobacter pylori, and
varices.
Propensity score analyses
Because this is a retrospective review of observational
data, there is a risk of inherent bias on selection of whether
an anesthesia professional (ADS) or endoscopist (EDS)
provides sedation. To help manage this bias, propensity
scores were calculated. A propensity score is the
probability of a treatment being assigned to a patient,
based on observed characteristics (collected covariates).
For this analysis, that treatment was whether or not ADS
was used. When using a propensity score, it is possible
to mimic some, but clearly not all, beneﬁts when doing
a randomized controlled trial.14 This score can be used
to adjust for the likelihood of inclusion in the ADS
(treatment) or EDS (nontreatment) groups, helping to
ensure that both groups are comparable for all observed
variables.15
For each colonoscopy and EGD in the cohort, a propen-
sity score was calculated. In this study we calculated
propensity scores measuring the likelihood that a given
procedure would use ADS versus EDS, regardless of the
actual sedation-provider status. A score was calculated
using separate multivariate logistic regression models for
colonoscopy and EGD. The output from each procedure
was assessed as a likelihood from 0% to 100% of having
used ADS, and this value was used in the logistic regression
analysis as a continuous predictor. Covariates included in
the model include all those used in the standard multivar-
iate logistic regression models as well as bowel prep re-
sults, depth of sedation intended, and all documented
procedure indications. Multivariate logistic regression ana-
lyses were performed to estimate the association between
sedation provider and risk of SAEs, adjusting for the
propensity to have used ADS.RESULTS
Patient demographics
Demographics of the 1,388,235 procedures evaluated
are shown in Table 1. There were 880,182 colonoscopies
and 508,053 EGDs. Mean patient age was 60.1 years
(standard deviation, 12.5) for colonoscopy and 58.4 years
(standard deviation, 15.9) for EGD. Most patients were
ASA physical classiﬁcation I/II (84% colonoscopy, 74%www.giejournal.orgEGD), outpatients, and received their procedures at a
community, health maintenance organization, or private
practice. ADS was used in 182,694 (21%) colonoscopy
procedures and 115,320 (23%) EGD procedures. Among
EDS procedures, the prevalence of propofol use was low
at 2.9% for colonoscopies and 2.5% EGDs.
Signiﬁcant adverse events
As stated above, an SAE was deﬁned as any event
requiring administration of cardiopulmonary resuscitation,
hospital or emergency department admission, administra-
tion of rescue/reversal medication, emergency surgery,
procedure termination because of an adverse event, intra-
procedural adverse events requiring intervention, or bloodVolume 85, No. 1 : 2017 GASTROINTESTINAL ENDOSCOPY 103
TABLE 2. SAE descriptive data
ADS EDS
Colonoscopy
No. of procedures 182,694 697,488
Total SAE rate 370 (.20%) 1952 (.28%)
Medication/sedation reversal 128 (.07%) 1143 (.16%)
Procedure stopped 71 (.04%) 309 (.04%)
Intraprocedural AEs requiring
intervention
46 (.03%) 256 (.04%)
Admit emergency department/
hospital
51 (.03%) 130 (.02%)
Airway management 51 (.03%) 81 (.01%)
Surgery 15 (.01%) 37 (.01%)
Adverse physiology with no
documented treatment
14 (.01%) 37 (.01%)
Cardiovascular rescue, no drug 1 (.00%) 28 (.00%)
Code 99/CPR 3 (.00%) 19 (.00%)
Blood transfusion 1 (.00%) 11 (.00%)
Other intervention* 47 (.03%) 158 (.02%)
EGD
No. of procedures 115,320 392,732
Total SAE rate 447 (.39%) 1247 (.32%)
Medication/sedation reversal 75 (.07%) 609 (.16%)
Procedure stopped 119 (.10%) 267 (.07%)
Intraprocedural AEs requiring
intervention
30 (.03%) 171 (.04%)
Admit emergency department/
hospital
45 (.04%) 112 (.03%)
Airway management 164 (.14%) 67 (.02%)
Surgery 6 (.01%) 15 (.00%)
Adverse physiology with no
documented treatment
5 (.00%) 14 (.00%)
Cardiovascular rescue, no drug 4 (.00%) 11 (.00%)
Code 99/CPR 10 (.01%) 23 (.01%)
Blood transfusion 13 (.01%) 54 (.01%)
Other intervention* 30 (.03%) 84 (.02%)
SAE, Serious adverse event; ADS, anesthesia-directed sedation; EDS, endoscopist-
directed sedation; CPR, cardiopulmonary resuscitation.
*Other includes Trendelenburg positioning, chin tilt w/suctioning, and other
advanced airway maneuvers.
TABLE 3. SAE risk stratified by procedure indication
n SAE %
Colonoscopy
Screening 358,867 .22
Surveillance 188,625 .26
Positive FOBT 40,691 .39
Hematochezia/melena/anemia 137,368 .33
Other nonbleed 154,631 .26
EGD
Barrett’s esophagus evaluation/
screening/surveillance
27,423 .19
Bleeding/varices/anemia 107,535 .59
Dysphagia 87,303 .34
Chest pain/dyspepsia 98,800 .13
GERD 75,306 .14
Nausea/vomiting 21,568 .23
Therapeutic intervention 13,566 .95
Other 76,552 .39
SAE, Serious adverse event; FOBT, fecal occult blood test.
A safety analysis of 1.38 million sedation procedures Vargo et altransfusion. Table 2 shows a descriptive breakdown of the
SAEs. Overall, for colonoscopy, EDS had a numerically
higher SAE rate (.28%) compared with ADS (.20%).
This increase is primarily because of an increased use of
rescue medications and reversal agents, where ADS used
only .07% compared with .16% for EDS. For EGD, ADS
had a numerically higher SAE rate (.39%) compared with
EDS (.32%). As with colonoscopy, there was a similar
rate of rescue medications/reversal agents used in both
groups, with EDS having an increased use (ADS .07%,
EDS .16%). Unlike colonoscopy, for EGD there was a104 GASTROINTESTINAL ENDOSCOPY Volume 85, No. 1 : 2017signiﬁcant increase in airway management-related SAEs
for ADS (.14%) compared with EDS (.02%).
The SAE risk stratiﬁed by procedure indication is shown
in Table 3. Although procedure indication was taken into
account in the multivariate logistic regression analysis,
the raw SAE rates were still assessed to determine what
inﬂuence it may have on the rates. For colonoscopy
patients with a positive fecal occult blood test (.39%)
or hematochezia/melena/anemia (.33%) indicated, the
SAE rate was higher compared with the other procedure
indications (.22%-.26%). For EGD patients with a
therapeutic intervention indicated (.95%), bleeding/
varices/anemia (.59%) had a higher SAE rate compared
with other indications (.13%-.39%).
Risk factors for SAEs: multivariate logistic
regression analysis
The results of the multivariate logistic regression analysis
are shown in Table 4. The most signiﬁcant predictor of SAE
risk was the ASA classiﬁcationwith an odds ratio (OR) of 5.85
(95% conﬁdence interval [CI], 4.24-8.06) for colonoscopy
and an OR of 7.01 (95% CI, 5.82-8.46) for EGD,
respectively, in ASA IV/V patients when compared with
their ASA I/II counterparts. Increasing age (75 years) was
also a signiﬁcant risk factor, with an OR of 3.53 (95% CI,
2.96-4.19) for colonoscopy and 2.06 (95% CI, 1.78-2.39)
for EGD versus patients younger than 50. Narcotic
administration resulted in an increased risk of SAEs as well
as sedative administration for colonoscopy procedures.
Compared with community/health maintenance
organization facilities, procedures performed at academic
(colonoscopy and EGD) and Veterans Affairs/military
(colonoscopy only) facilities had an increased risk of SAEs.www.giejournal.org
TABLE 4. SAE risk multivariate logistic regression*
Colonoscopy
OR [95% CI]
EGD
OR [95% CI]
Age (reference: <50 y)
50-64 y 1.66 [1.41-1.96] 1.29 [1.12-1.48]
65-74 y 2.59 [2.19-3.07] 1.43 [1.23-1.67]
75 y 3.53 [2.96-4.19] 2.06 [1.78-2.39]
7 Sex (reference: female)
Male 1.05 [.96-1.15] 1.07 [.96-1.19]
ASA classification
(reference: I/II)
III 1.79 [1.59-2.01] 2.52 [2.25-2.82]
IV/V 5.85 [4.24-8.06] 7.01 [5.82-8.46]
Unknown .95 [.78-1.16] 1.48 [1.21-1.80]
Narcotic administered
(reference: no)
Yes 1.53 [1.29-1.82] 1.26 [1.07-1.48]
Unknown 1.26 [.82-1.94] 1.21 [.80-1.83]
Sedative administered
(reference: no)
Yes 1.50 [1.01-2.23] 1.22 [.83-1.81]
Trainee present
(reference: no)
Yes 1.07 [.95-1.21] 2.06 [1.82-2.34]
Site type (reference:
community/HMO)
Academic 1.52 [1.34-1.73] 1.17 [1.02-1.35]
VA/military 1.56 [1.38-1.76] .94 [.81-1.10]
Sedation provider
(reference: EDS)
ADS 1.18 [.99-1.39] 1.34 [1.13-1.58]
SAE, Serious adverse event; ASA, American Society of Anesthesiologists; HMO, health
maintenance organization; EDS, endoscopist-directed sedation; ADS, anesthesia-
directed sedation.
*Adjusted for age, gender, ASA classification, narcotic administration, sedative
administration, trainee present, site type, sedation provider, and indication
(colonoscopy: screening vs surveillance vs positive fecal occult blood test vs other;
EGD: Barrett’s screening/surveillance, gastric polyps/ulcer, H pylori, varices).
TABLE 5. SAE risk stratified by site type and presence of a trainee
Sedation provider
Colonoscopy
% of group
with SAE
EGD
% of group
with SAE
Community/HMO EDS ADS EDS ADS
Trainee present .32 .00 .92 1.08
Trainee not present .22 .19 .22 .29
Academic
Trainee present .39 .29 .55 .93
Trainee not present .36 .45 .32 .74
VA/military
Trainee present .43 1.27 .54 .91
Trainee not present .37 .38 .25 .48
SAE, Serious adverse event; HMO, health maintenance organization; EDS,
endoscopist-directed sedation; ADS, anesthesia-directed sedation; VA, Veterans
Affairs.
Vargo et al A safety analysis of 1.38 million sedation proceduresThe presence of a trainee also increased the risk of SAEs
for EGD procedures. Table 5 provides the SAEs for EGD
and colonoscopy stratiﬁed by the presence of a trainee, the
sedation provider, and the site type. Consistent with the
increased risk of SAEs, for EGD procedures the presence
of a trainee was associated with a higher rate of SAEs at all
3 site types and both sedation providers. SAEs were more
prevalent with ADS in both the trainee-present and trainee-
not-present groups. The most signiﬁcant difference was
seen at the community/health maintenance organization
sites (EDS: trainee present .92%, trainee not present .22%;
ADS: trainee present 1.08%, not present .29%). For colonos-
copy there were no differences seen across all 3 site types
and both sedation providers, except for the Veterans Af-
fairs/military sites with ADS, which had the highest observed
rate (trainee present 1.27%, trainee not present .38%).www.giejournal.orgSedation provider and risk of SAE: regression
analysis adjusted for propensity score
In multivariate logistic regression analysis, the use of
ADS was associated with an increased risk for SAEs
when compared with EDS for EGD (OR, 1.34; 95% CI,
1.13-1.58), as shown in Table 4. There was no statistical
difference for colonoscopy, with an OR of 1.18 (95% CI,
.99-1.39) for colonoscopy. To better assess this result of
whether ADS is associated with an increased SAE risk,
a propensity-adjusted risk assessment for SAEs was
performed, with the results shown in Table 6. For
colonoscopy, after adjusting for the likelihood
(propensity) of using ADS, the risk of an SAE was still
not signiﬁcantly different between ADS and EDS, with an
OR of .93 (95% CI, .82-1.06). For EGD, after adjusting for
the likelihood (propensity) of seeing an anesthesia
professional, the risk of SAEs was greater when sedation
was provided by an anesthesia professional, with an OR
of 1.33 (95% CI, 1.18-1.50).Sedation provider and risk of SAE: stratiﬁed
by ASA classiﬁcation
To further evaluate the association between ADS and
the risk of SAEs for EGD, multivariate logistic regression
analysis was used on data stratiﬁed by ASA I/II and ASA
III to see whether there was a difference in SAE risk for
these 2 populations. The results are shown in Table 6,
for all patients and also stratiﬁed by ASA I/II and ASA III.
There was an insufﬁcient number of ASA IV/V patients
(<10,000) to include that stratiﬁcation. For colonoscopy,
neither group had an increased risk of SAE if ADS was
used (ASA I/II with an OR of .91 [95% CI, .77-1.06] and
ASA III with an OR of .90 [95% CI, .69-1.16]). For EGD,
both groups had an increased risk of SAE if ADS was
used (ASA I/II with an OR of 1.26 [95% CI, 1.03-1.54] and
ASA III with an OR of 1.38 [95% CI, 1.14-1.67]).Volume 85, No. 1 : 2017 GASTROINTESTINAL ENDOSCOPY 105
TABLE 6. SAE risk EDS vs ADS multivariate logistic regression adjusted for propensity score*
Colonoscopy
OR [95% CI]
EGD
OR [95% CI]
All ASA classes [95% CI]
Sedation provider (reference: EDS)
ADS .93 [.82-1.06] 1.33 [1.18-1.50]
ASA I/II [95% CI] n Z 741,536 (1,797 events)
Sedation provider (reference: EDS)
ADS .91 [.77-1.06] 1.26 [1.03-1.54]
ASA III [95% CI] n Z 72,255 (412 events)
Sedation provider (reference: EDS)
ADS .90 [.69-1.16] 1.38 [1.14-1.67]
SAE, Serious adverse event; EDS, endoscopist-directed sedation; ADS, anesthesia-directed sedation; ASA, American Society of Anesthesiologists.
*Adjusted for age, gender, ASA classification, narcotic administration, sedative administration, trainee present, site type, sedation provider, and indication (colonoscopy:
screening vs surveillance vs positive fecal occult blood test vs other; EGD: Barrett’s screening/surveillance, gastric polyps/ulcer, H pylori, varices).
TABLE 7. Mortality
Incidence Mean age (SD) ASA class (n) AP sedation (n)
Colonoscopy 3 59.0 (16.3) I (1), III (2) 0
Patient 1 Vasovagal reaction; arrhythmia, bradycardia, and hypotension
Patient 2 Collapsed 1 hour at home; brought to hospital, refractory ventricular fibrillation
Patient 3 Hypoxemia during the procedure
EGD 7 64.0 (15.2) II (1), III (5), IV (1) 1
Patient 4 Vasovagal reaction; arrhythmia, bradycardia, and hypotension
Patient 5 Sinus tachycardia, then idioventricular rhythm (rate in 30s and 40s), hypotension
Patient 6 Intraprocedural bradycardia
Patient 7 Bleed resulting in hypotension
Patient 8 Prolonged hypoxia resulting in cardiopulmonary arrest
Patient 9 Transferred to emergency department, died from hypotension 2 days later
Patient 10 Unresponsive with normal vitals, unable to palpate a pulse
SD, Standard deviation; ASA, American Society of Anesthesiologists; AP, anesthesia professional.
A safety analysis of 1.38 million sedation procedures Vargo et alMortality
Mortality results are shown in Table 7. Ten patient deaths
occurred in the patient population of 1,388,235 (1/138,824
patients). Three deaths occurred during a colonoscopy and
7 during an EGD. Only 1 of the colonoscopy deaths was
potentially related to over-sedation (patient 3), resulting
in a rate of 1 of 880,182 for colonoscopy. Stratifying by seda-
tion provider, the rates are similar at 1 of 697,488 for EDS
and 0 of 182,694 for ADS.
Five deaths in the EGD group were potentially because
of over-sedation (patients 5, 6, 8, 9, and 10), resulting in a
rate of 5 of 508,053 (approximately 1/101,611). Stratifying
by sedation provider, the rates are similar for EDS (w1/
98,183) and ADS (1/115,320).DISCUSSION
There has been a substantial increase in sedation
for routine endoscopic procedures being provided by106 GASTROINTESTINAL ENDOSCOPY Volume 85, No. 1 : 2017anesthesia professionals, with rates regionally exceeding
50%.2-4 This results in increased costs of endoscopic proce-
dures, at a time when the cost of health care is putting a
severe strain on the system. Additionally, in certain areas
of the United States there is a shortage of anesthesia pro-
viders, so special consideration must be taken to ensure
the proper allocation of limited health care resources.16
In light of the decision of the Centers for Medicare &
Medicaid Services to pay for anesthesia services for all
screening colonoscopies, the potential safety and quality
beneﬁts need to be critically deﬁned, especially given
that most of the increase in anesthesia services has been
seen in low-risk patients.5,16,17
This study of 1.38 million procedures from 84 practice
sites, including university medical centers, Veteran Affairs
Health Care Systems, and gastroenterology private prac-
tices, addresses the safety aspect of that question. The
sample size of 1.38 million procedures using propensity
score analysis allows for a large number of covariates to
be accounted for, providing greater conﬁdence in thewww.giejournal.org
Vargo et al A safety analysis of 1.38 million sedation proceduresresults. A prospective study of sufﬁcient size will not be
conducted given the logistical complexity and costs. There-
fore, CORI-NED’s large database allows a robust analysis of
safety outcomes as a function of the sedation provider. We
found that the propensity-adjusted SAE risk for pooled ASA
physical classiﬁcation patients undergoing ADS was similar
to EDS for colonoscopy but higher for EGD procedures.
Additionally, with further stratiﬁcation into ASA class I/II
and III, the use of ADS was associated with higher odds
for an SAE for ASA I/II/III subjects undergoing upper
endoscopy. When dichotomized into ASA I/II and ASA III
for patients undergoing colonoscopy, the SAE risk for
ADS and EDS was similar.
Several other risk factors were signiﬁcantly associated
with an increased risk of SAE beyond ASA and the sedation
provider. These included patient age, the presence of a
trainee, and academic or military/Veterans Affairs site
type. Certain indications for colonoscopy or EGD had
higher raw rates as well. It is not surprising that patient
factors (age, comorbidity), procedures with a higher like-
lihood of therapeutic interventions, or the presence of
less-trained endoscopists would be associated with SAEs.
A possibility exists of a synergy between risk factors that
played a role, as Table 5 suggests. However, controlling
for these factors in multivariate logistic and propensity-
adjusted analyses did not eliminate the signiﬁcant associa-
tion between ADS and SAEs in EGD procedures.
The fact that the raw SAE rate for colonoscopy of .20%
for ADS compared with .28% for EDS failed to reach signif-
icance, whereas for EGD .39% for ADS compared with .32%
for EDS did reach statistical signiﬁcance warrants some
discussion. It is important to note that these are raw inci-
dence rates and do not account for confounding variables.
When age, gender, ASA classiﬁcation, narcotic use, sedative
status, trainee presence, site type, and indication are taken
into account, no signiﬁcant association is found between
sedation provider and colonoscopy. Therefore, although
EDS does have a higher rate when not including confound-
ing factors, once confounding factors are taken into
account there is no longer an increase seen in the SAE
rate for colonoscopy. A trend seen in the EDS group for
colonoscopy and EGD alike was an increase in the use of
rescue and reversal medications compared with ADS.
This, in part, may be because EDS is done with traditional
benzodiazepine/narcotic-based sedation where a reversal
medication is available, compared with ADS, which pre-
dominantly uses propofol-based sedation, where a reversal
agent is not available. Of note, for EGD procedures, ADS
had signiﬁcantly more airway-management SAEs.
The retrospective design of this study is a potential
weakness. The data collected in the NED database do
not contain all potential demographic and procedural
data, such as body mass index and Mallampati score.
One of the key procedural data points missing from the
database is the type of sedation given by the provider
(the targeted level of sedation and if the patient waswww.giejournal.orgintubated or not). In addition to demographic and
procedural data, we also cannot be assured that all events
identiﬁed in this study as an SAE were captured, especially
less signiﬁcant events such as the use of a nasal or oral
airway. The propensity score analysis, although superior
to a simple regression analysis, still will have some hidden
biases in the match results, factors that were not observed
that can inﬂuence the scores. Although it mimics some
beneﬁts of a randomized controlled trial, it should not
be confused as being equivalent to a randomized
controlled trial. It must be emphasized that, to our knowl-
edge, this is the ﬁrst time this methodology has been
applied to the question of endoscopic sedation and
SAEs, representing a robust attempt to remove bias
in addition to the traditional multivariate analysis with
adjustment.
As previously mentioned, no study has been published
showing a quality beneﬁt based on the method of sedation
(polyp detection or adenoma detection rate).8,9,18,19 One
beneﬁt seen with anesthesia professionals using propofol
is patient satisfaction. In a meta-analysis of 36 moderate
sedation studies, propofol sedation provided slightly
more patient satisfaction when compared with midazolam
plus narcotics.20 It is unclear if the increase in patient
satisfaction is because of the presence of an anesthesia
professional or the use of propofol.
For safety, a smaller retrospective study of 118,004
colonoscopies compared propofol and nonpropofol
administration (fentanyl, midazolam, meperidine, and/or
diazepam), showing a 2.5-increased rate in colonoscopic
perforations for therapeutic colonoscopies (6.9 vs 2.7 per
10,000; P Z .0015) in the propofol administration group
(administered by anesthesia professionals).11,13 Another
study of 165,527 colonoscopies in 100,359 patients found
an increased risk of aspiration pneumonia when sedation
was delivered by an anesthesia professional.12 Most
recently, a claims data analysis of more than 3 million
colonoscopies found a 13% increase in 30-day adverse
events when anesthesia was used.21 Although an
increased risk of an SAE with colonoscopy was not seen
in this study, an association for SAEs that might present
or be diagnosed in a delayed fashion cannot be excluded.
This study addresses the question of safety with a
comprehensive view of patient risk, assessed by the SAE
rate, a signiﬁcantly greater size compared with most other
retrospective studies, particularly those using endoscopic
reports or patient medical records. It accounts for many
covariates both in the logistic regression analysis and the
propensity score analysis. Most data was for ASA I/II/III pa-
tients. In reviewing the data, pooled and stratiﬁed by ASA
classiﬁcation I/II and III, it appears there is no clinical safety
beneﬁt with ADS. In fact, in the case of EGD, ADS is
associated with an increased risk of SAEs for ASA I, II,
and III patients. It is clear from the data and the conﬁnes
of our SAE deﬁnition set that ADS does not reduce the
risk of an SAE when compared with EDS.Volume 85, No. 1 : 2017 GASTROINTESTINAL ENDOSCOPY 107
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anesthesia professional in reducing the SAE incidence,
including ASA III patients, who are more likely to experi-
ence an SAE. There are several potential reasons that
ADS sedation may not confer a beneﬁt. The most likely
possibility is the level of sedation. Anesthesia professionals
are trained to provide deep sedation and general anes-
thesia, levels of sedation that have increased risks of an
SAE. Additionally, the level of sedation may not be aligned
with the procedure, resulting in extended periods of
over-sedation, especially during reduced stimulus. In
EGD patients, where an increase in SAE risk was seen,
deeper levels of sedation likely blunted protective reﬂexes,
perhaps contributing to the increase in the risk for cardio-
pulmonary unplanned events. The collected data do not
allow us to determine if the increased risk for EGD is
because of aspiration or respiratory depression. Future
studies would be useful to understand the reason and
provide clinical insight into how to reduce this risk. Other
reasons that could account for this include drug selection
(eg, propofol), polypharmacy, and other unmeasured
patient and procedure variability.
Given the small sample size of ASA IV/V patients in the
database, no conclusions can be drawn for these patients
from this analysis, especially given the fact that very few
did not use an anesthesia professional. The database
appears to reﬂect actual colonoscopy/EGD procedures
where most procedures are outpatient compared with
inpatient. In this study an ASA classiﬁcation of IV/V was
the most signiﬁcant predictor for risk of an SAE. For those
patients with an ASA classiﬁcation of IV or V or with other
complicating factors, it is clinically appropriate that these
patients have an ADS provide the sedation for the proce-
dure, as recommended per the ASA guidelines.22
Based on this analysis of over 1.38 million endoscopic
procedures, the use of anesthesia professionals to provide
sedation did not reduce the rate of the measured signiﬁ-
cant adverse events in ASA I, II, and III patients undergoing
colonoscopy or EGD. In fact, the ﬁndings of this study
suggest that ADS for EGD increases the risk of SAEs. The
ﬁndings do not exclude a likely safety beneﬁt for higher
risk patients (ASA IV/V) with high comorbidity where the
airway management and cardiovascular support skills of
the anesthesia professional are necessary. For most pa-
tients undergoing standard upper- and lower-endoscopic
procedures, it is difﬁcult to justify the use of anesthesia
professional services based on reasons of safety.REFERENCES
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